622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

Bibliographic Details
Main Authors:	C Daniel De Magalhaes Filho, Chung-Wein Lee, Nikolai Suslov, Jerry Fong, Miguel Garcia-Guzman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma
by: Nanami L. Miyazaki, et al.
Published: (2023-10-01)

675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)
by: Yiran Zhang, et al.
Published: (2023-11-01)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

DISEASE RECURRENCE PREDICTORS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Yuniardini S. Wimardhani, et al.
Published: (2015-06-01)

Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
by: J Gilbert, et al.
Published: (2007-01-01)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01)

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
by: Marc Hamoir, et al.
Published: (2018-08-01)

The Role of MicroRNAs in Recurrence and Metastasis of Head and Neck Squamous Cell Carcinoma
by: Chris X. Yang, et al.
Published: (2019-03-01)

Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma
by: Tomonori Kaneko, et al.
Published: (2022-07-01)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
by: Greg M Delgoffe, et al.
Published: (2021-05-01)

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck
by: Sebastian Zahnreich, et al.
Published: (2021-02-01)

Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck
by: Dana M. Hartl, et al.
Published: (2023-09-01)

Opportunities and Limits in Salvage Surgery in Persistent or Recurrent Head and Neck Squamous Cell Carcinoma
by: Gerhard Frank Huber
Published: (2021-05-01)

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
by: Jochen H Lorch
Published: (2009-11-01)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Athanassios Argiris, et al.
Published: (2017-05-01)

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
by: Kate Clancy, et al.
Published: (2021-09-01)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
by: Stefano Cavalieri, et al.
Published: (2021-12-01)

Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
by: Behrus Puladi, et al.
Published: (2021-08-01)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
by: Juan L. Callejas-Valera, et al.
Published: (2022-05-01)

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
by: Ilaria Girolami, et al.
Published: (2023-02-01)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
by: D. Evrard, et al.
Published: (2020-01-01)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Edith Borcoman, et al.
Published: (2021-05-01)

NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
by: A. M. Mudunov, et al.
Published: (2017-06-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

Patterns of recurrence after low-dose postoperative radiotherapy for head and neck squamous cell carcinoma
by: Wataru Makino, et al.
Published: (2021-12-01)

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas
by: Valentina Lupato, et al.
Published: (2021-01-01)

Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma
by: Daniela Schulz, et al.
Published: (2021-12-01)

HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines
by: Maria Paula Gomez Hernandez, et al.
Published: (2019-09-01)

Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma
by: Kanako Yoshimura, et al.
Published: (2021-10-01)

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
by: Won Jin Ho, et al.
Published: (2018-08-01)

Immunotherapy in Head and Neck Squamous Cell Cancer
by: Nerina Denaro, et al.
Published: (2018-12-01)

Exosomes in Head and Neck Squamous Cell Carcinoma
by: Cheng Xiao, et al.
Published: (2019-09-01)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis
by: Dylan A. Levy, et al.
Published: (2022-09-01)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
by: Jean-Philippe Foy, et al.
Published: (2022-10-01)

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients
by: Lu Li, et al.
Published: (2023-07-01)